Subscribe to RSS
DOI: 10.1055/s-0029-1186201
© Georg Thieme Verlag KG Stuttgart · New York
Cardiac Valve Replacement in Patients with End-Stage Renal Failure: Impact of Prosthesis Type on the Early Postoperative Course[*]
Publication History
received February 27, 2009
Publication Date:
13 January 2010 (online)
![](https://www.thieme-connect.de/media/thoracic/201001/lookinside/thumbnails/10.1055-s-0029-1186201-1.jpg)
Abstract
Background: It is still unclear whether biological or mechanical valves should be preferred in patients on chronic dialysis therapy. Patients and Methods: We retrospectively analyzed data from 104 patients (66.5 ± 8.6 years) with end-stage renal failure (RF) who underwent aortic or mitral valve replacement between 2002 and 4/2008. Mechanical valves were implanted in 44 (42 %) patients and bioprostheses in 60 (58 %). The two groups were comparable with regard to preoperative data, age and incidence of additional CABG procedures. We studied in-hospital morbidity and mortality, major postoperative complications and length of ICU and hospital stay. Additionally, parameters predicting a poor outcome were analyzed with multivariate regression analysis. Results: The overall hospital mortality was 12.5 % and did not differ between the two groups (mechanical: 13.6 %, biological: 11.7 %, n. s.). In the postoperative course, duration of ventilation and ICU stay were similar, whereas hospital stay was significantly longer for patients with mechanical prostheses (19.5 ± 5.4 vs. 15.6 ± 4.1 days, p < 0.05). Mechanical valve patients had a significantly higher rate of postoperative cerebrovascular incidents (18.2 vs. 8.3 %, p < 0.05) and bleeding complications (15.9 vs. 11.7 %, p < 0.05). Reoperation, obesity, left ventricular ejection fraction < 30 % and previous neurological complications were independent predictors of hospital mortality. Conclusions: Our results demonstrate that in patients with end-stage RF, the use of mechanical valves is associated with a significant risk of complications. Because of the poor overall survival of patients on dialysis, bioprosthesis degeneration will not be a limiting factor. Therefore, preference should be given to biological valves in these patients.
Key words
heart valve surgery - renal failure - mortality - prognostic markers
1 The content of this paper was presented during the 38th annual meeting of the German Society of Thoracic- and Cardiovascular Surgery on February 15–18, 2009 in Stuttgart, Germany.
References
- 1 Herzog C A, Ma J Z, Collins A J. Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified?. Circulation. 2002; 105 1336-1341
- 2 Bonow R O, Carabello B, de Leon A C, Edmunds Jr L H, Fedderly B J, Freed M D, Gaasch W H, McKay C R, Nishimura R A, O'Gara P T, O'Rourke R A, Rahimtoola S H, Ritchie J L, Cheitlin M D, Eagle K A, Gardner T J, Garson Jr A, Gibbons R J, Russell R O, Ryan T J, Smith Jr S C. ACC/AHA Guidelines for the management of patients with valvular heart disease. Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Heart Valve Dis. 1998; 7 672-707
- 3 Bonow R O, Carabello B A, Kanu C, de Leon Jr A C, Faxon D P, Freed M D, Gaasch W H, Lytle B W, Nishimura R A, O'Gara P T, O'Rourke R A, Otto C M, Shah P M, Shanewise J S, Smith Jr S C, Jacobs A K, Adams C D, Anderson J L, Antman E M, Faxon D P, Fuster V, Halperin J L, Hiratzka L F, Hunt S A, Lytle B W, Nishimura R, Page R L, Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 2006; 114 e84-e231
- 4 Brinkman W T, Williams W H, Guyton R A, Jones E L, Craver J M. Valve replacement in patients on chronic renal dialysis: implications for valve prosthesis selection. Ann Thorac Surg. 2002; 74 37-42
- 5 Fann J I, Miller D C, Moore K A, Mitchell R S, Oyer P E, Stinson E B, Robbins R C, Reitz B A, Shumway N E. Twenty-year clinical experience with porcine bioprostheses. Ann Thorac Surg. 1996; 62 1301-1311
- 6 Fishbein M C, Gissen S A, Collins Jr J J, Barsamian E M, Cohn L H. Pathologic findings after cardiac valve replacement with glutaraldehyde-fixed porcine valves. Am J Cardiol. 1977; 40 331-337
- 7 Lamberti J J, Wainer B H, Fisher K A, Karunaratne H B, Al-Sadir J. Calcific stenosis of the porcine heterograft. Ann Thorac Surg. 1979; 28 28-32
- 8 Bechtel U, Mucke C, Feucht H E, Schiffl H, Sitter T, Held E. Limitations of pulse oral calcitriol therapy in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis. 1995; 25 291-296
- 9 Kaplon R J, Cosgrove III D M, Gillinov A M, Lytle B W, Blackstone E H, Smedira N G. Cardiac valve replacement in patients on dialysis: influence of prosthesis on survival. Ann Thorac Surg. 2000; 70 438-441
- 10 Lucke J C, Samy R N, Atkins B Z, Silvestry S C, Douglas Jr J M, Schwab S J, Wolfe W G, Glower D D. Results of valve replacement with mechanical and biological prostheses in chronic renal dialysis patients. Ann Thorac Surg. 1997; 64 129-132
- 11 Holden R M, Sanfilippo A S, Hopman W M, Zimmerman D, Garland J S, Morton A R. Warfarin and aortic valve calcification in hemodialysis patients. J Nephrol. 2007; 20 417-422
- 12 Rao A K, Djamali A, Korcarz C E, Aeschlimann S E, Wolff M R, Stein J H. Mitral annular calcification is associated with reduced left ventricular function and inflammation in patients with chronic kidney disease. J Am Soc Echocardiogr. 2008; 21 747-750
- 13 Filsoufi F, Chikwe J, Castillo J G, Rahmanian P B, Vassalotti J, Adams D H. Prosthesis type has minimal impact on survival after valve surgery in patients with moderate to end-stage renal failure. Nephrol Dial Transplant. 2008; 23 3613-3621
- 14 Chan V, Jamieson W R, Fleisher A G. Valve replacement surgery in end-stage renal failure: mechanical prostheses versus bioprostheses. Ann Thorac Surg. 2006; 81 857-862
- 15 Torpy J M, Lynm C, Glass R M. JAMA patient page. Evidence-based medicine. JAMA. 2006; 296 1192
- 16 Ruel M, Chan V, Bedard P, Kulik A, Ressler L, Lam B K, Rubens F D, Goldstein W, Hendry P J, Masters R G, Mesana T G. Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults < 60 years of age. Circulation. 2007; 116 I294-I300
1 The content of this paper was presented during the 38th annual meeting of the German Society of Thoracic- and Cardiovascular Surgery on February 15–18, 2009 in Stuttgart, Germany.
Dr. PD Dr. Udo Boeken
Department of Thoracic and Cardiovascular Surgery
University Hospital
Moorenstrasse 5
40225 Duesseldorf
Germany
Email: boeken@uni-duesseldorf.de